PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2113942
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2113942
According to Mordor Intelligence, the spinal non-fusion devices market size in 2026 is estimated at USD 4.03 billion, growing from 2025 value of USD 3.85 billion with 2031 projections showing USD 5.03 billion, growing at 4.58% CAGR over 2026-2031.

This report is Segmented by Product (Artificial Cervical Disc, Artificial Lumbar Disc, Dynamic Stabilization Devices, and More), End User (Hospitals, Ambulatory Surgical Centers, and More), Surgery Type (Open Spine Surgery, Minimally-Invasive Surgery), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Clinical practice is moving decisively from fusion-first protocols to motion-preservation pathways. Prospective evidence shows anterior cervical hybrid constructs preserve 16.3° of segmental motion versus 4.7° in multilevel fusion, a functional edge that correlates with lower revision rates. Facet arthroplasty devices such as TOPS reported 93% patient satisfaction in FDA trials, reinforcing economic value despite higher up-front cost. Surgeon preference for physiologic kinematics is therefore translating into robust purchasing momentum across the spinal non-fusion devices market.
An aging global population is driving sustained procedural volume, with Medicare data predicting significant expansion in spinal instrumentation demand through 2050. Earlier imaging-driven diagnosis favors motion-preserving interventions before irreversible damage, enlarging the spinal non-fusion devices market. Younger cohorts also value implants that minimize the need for later revision, intensifying long-run demand.
Hospitals face 20% jumps in shipping, labor and raw-material expenses, leading to tighter capital allocation that slows premium implant adoption. France's reimbursement cuts for orthopedic hardware underscore mounting price pressure, dampening near-term volume in the spinal non-fusion devices market.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Artificial cervical discs captured 34.62% revenue in 2025 and remain the anchor of the spinal non-fusion devices market. Long-term data on Mobi-C show lower adjacent-segment pathology compared with fusion, reinforcing surgeon preference. The spinal non-fusion devices market size for artificial cervical discs stood at USD 1.33 billion in 2025 and is expanding steadily at a mid-single-digit rate.
Nucleus and annulus repair implants are on track for a 6.39% CAGR through 2031, reflecting regenerative-medicine traction and growing funding. Their share of the spinal non-fusion devices market size is set to rise as clinical trials confirm sustained disc-height restoration. Dynamic stabilization systems hold notable share through biomechanical superiority, whereas interspinous spacers lag amid mixed coverage decisions. Facet joint replacements and other emerging devices contribute incrementally but hold long-run upside as evidence builds.
North America delivered 41.74% revenue in 2025 on the back of mature reimbursement and high surgeon training density. FDA clearances, such as the VELYS Spine platform, highlight continual integration of implants with navigation and robotics ecosystems. Coverage refinements around cervical disc replacement further secure volume growth, keeping the spinal non-fusion devices market buoyant.
Asia-Pacific is poised for the fastest regional CAGR of 5.68% through 2031, propelled by demographic aging and infrastructure upgrades. China's streamlined device-registration catalogue accelerates time-to-market, enlarging the spinal non-fusion devices market in a nation where hospital build-outs remain strong. Japan's adoption of advanced robotics and its super-aged society create robust demand, though clinical-evidence expectations remain rigorous.
Europe faces intensified cost-containment but continues to drive steady, evidence-based uptake. CE pathways for regenerative implants demonstrate regulatory openness, yet national budget caps may slow early-stage adoption. South America and Middle East & Africa present long-term opportunities as private hospital chains invest in advanced spine suites, although current volumes remain modest due to affordability and workforce constraints.